Global CAR T Cell Therapy Market, By Targeted Antigen,
Therapeutic Application, and Geography - Trends,
Analysis and Forecast till 2028
In the recent past, cancer therapy such as targeted immunotherapies that includes CAR-T cell
therapies is been preferred over surgery, chemotherapy, and radiation. These target cancer cells
and strengthen the patient’s immune system against the tumor. CAR-T cell therapy is a type of
treatment in which T-cells derived from patient’s blood are modified in laboratory with the
addition of a special protein receptor on the T-cells that attack cancer cells. This special
receptor is known as Chimeric Antigen Receptor (CAR) that binds to specific protein on
patient’s cancer cells. Millions of CAR-T cells are grown in the laboratory and then
administered in the patients through infusion. These cells bind to the infected cancer cells and
have the ability to kill them thereby leading to curing of the cancer. Masking of cancer cells
from immune cells can be combated by the incorporation of immune checkpoint inhibitors in
body which can detect and inhibit cancer cells. This innovative approach of using the body’s
immune cells to target cancer causing cells has been successful used in the treatment of
pediatric relapsed acute lymphoblastic leukemia, refractory non-Hodgkin lymphoma, and other
cancers.
For In depth Information Get Sample Copy of this Report @
https://www.coherentmarketinsights.com/insight/request-sample/102
The global CAR-T Cell therapy market is estimated to be valued at US$ 295.1 million in 2018
and is expected to witness a CAGR of 32.5 % over the forecast period (2018 – 2028).
Market Dynamics
CAR-T cell therapy is expected to be an important development in cancer treatment and
therapeutics industry due to its cost efficiency. Moreover, rising incidence of cancer is leading
to high demand for its treatment. According to the World Cancer Research Fund International
(WCRFI), around 14.1 million cancer cases were reported worldwide, in 2012. As per WCRFI, it
is projected that by 2035, around 24 million cancer cases would be observed worldwide.
Moreover, introduction of new therapies into the market is further expected to bolster growth
of CAR-T cell therapy market. For instance, in October 2017, the U.S. Food and Drug